Promising Future Outlook for US Generics Industry

As per our new research report “Booming US Generic Drug Market”, the US generics market has witnessed healthy growth rate over the past few years. The share of generics in the total pharmaceutical prescription surged from 19% in 1984 to around 70% in 2008. Our extensive research and profound analysis reveals that the US generics market holds immense growth potential with promising future prospects. With the patent expiration of key blockbuster drugs and supporting government, it is expected that the market will grow at a CAGR of around 9% during 2010-2012.

 

We have identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that rapidly aging population and increasing pressure from insurance firms to cut healthcare costs will give impetus to the US generics market. We have noted that during 2008-2012, patents of blockbusters valued more than US$ 60 Billion are going to expire. This expiration will enable the biogenerics market to register strong growth in near future. The report also discusses the potential of generic drugs in various therapeutics segments of the pharmaceutical industry, which will give a clear idea about the type of products available in the market.

 

We believe that the regulatory environment plays a critical role in the development of generic drugs industry, and our report provides a complete overview of the US regulatory environment. Besides, the report discusses several industry bottlenecks obstructing the generics industry growth.

 

“Booming US Generic Drug Market” provides an extensive research and conceptual analysis of the generic drugs market in the US. It covers various growth supporting factors like macroeconomic environment, healthcare reform plans. The report thoroughly examines the current market trends; industrial developments and competitive landscape to enable clients understand the market structure and its progress in coming years. Forecast in this research report has been made considering the possible post-recession impact on the industry. Thus, it provides valuable information to pharmaceutical & generics companies and investors looking to enter this market.

For more information visit: http://www.rncos.com/Report/IM589.htm